



August 28, 2025

Collaborative Partnership between IQVIA and TRICALS

Amyotrophic Lateral Sclerosis (ALS), also known as motor neurone disease (MND) or Lou Gehrig's Disease (LGD) in the US, is a progressive neurodegenerative disease. Although relatively rare, with 2 new cases per 100,000 people each year, its impact is devastating, profoundly affecting patients and their families. There is currently no known cure, but significant advances in promising novel treatments offer hope.

IQVIA, a leading global provider of clinical research services, commercial insights, and healthcare intelligence, has partnered with TRICALS (Treatment Research Initiative to Cure ALS), the largest European research initiative aimed at finding a cure for ALS. This collaboration combines TRICALS' scientific knowledge and extensive site network with IQVIA's data, science, and operational capabilities to develop new medicines for ALS.

A cornerstone of this effort is the MAGNET initiative (Multi-Adaptive Global Network of ALS Clinical Trials), which offers a full-service solution for conducting Phase II and III ALS trials within a competitive budget.

The MAGNET initiative builds on the strength of TRICALS and IQVIA as a preferred CRO to enable the following:

- Input from the TRICALS network of over 60 certified centres to help design and perform your study, including insights from patient organizations
- Innovative template protocol designs, with design elements approved in advance by regulatory authorities, ensuring studies are designed in the optimal way while offering flexibility of approach
- Start-up efficiencies through working with the existing TRICALS infrastructure, including contract templates and budgets designed to streamline study set-up
- The promise of recruitment delivery through the specialist centres that form the TRICALS network, supported by IQVIA in enabling operational delivery

As well as the provision of clinical trial management, IQVIA is proud to have been the global partner supporting TRICALS in the development of their 'Precision ALS' platform. This innovative platform facilitates the collection and utilization of incident and prevalent patient

data across the extensive network of TRICALS research sites , providing critical insights into the ALS population and accelerating the journey towards effective treatments. PRECISION ALS revolutionizes the way patient data is gathered and utilized , and by leveraging IQVIA's vast global experience in healthcare data analytics, the Precision ALS platform will provide new insights into the heterogeneity of ALS, develop better markers of different disease subtypes, better data-driven outcome measures, better insights into important social determinants of health that affect disease risk and outcome, and provide new ways to match the right patient to the right drug in a clinical trial setting. The platform, in research collaboration with IQVIA, will continue to support TRICALS in ensuring that all patient data is utilized responsibly and in full compliance with all relevant legislation and data protection standards.

Additional Key Areas of Collaboration:

- **Optimizing Study Designs and Research Protocols:** IQVIA's strategic drug development experience and global operational capabilities, combined with TRICALS' academic expertise, ensure that study protocols are optimally designed to address key questions related to the ALS patient population.
- **Supporting More Clinical Research Sites:** While TRICALS collaborates with over 60 research centers in 17 European countries, IQVIA brings its operational experience in supporting these sites, enabling research teams to be 'trial ready' and ensuring consistency of approach through training and education.
- **Efficiently Operationalizing Clinical Trial Programs:** IQVIA, as a leading CRO with extensive experience in running global clinical trial programs, including in the field of ALS, will support TRICALS in efficiently operationalizing these programs, delivering quality study results that will serve as the basis for market authorizations of new and innovative treatments. Furthermore, IQVIA and TRICALS will work in partnership to conduct scientific discussion forums where developments in the field of ALS can continue to be explored.

The collaboration between IQVIA and TRICALS aims to bring together data and ALS-specific business intelligence to deliver optimal strategies and solutions for the ALS population, advancing clinical research in this field. This partnership will support industry sponsors by enabling them to develop tailor-made strategies through insights derived from the ALS patient population. Ultimately, this collaboration will support sponsors in developing potential treatments more quickly and cost-effectively, bringing the goal of a treatment for ALS closer to reality.

Source: **IQVIA blog**

European organization for Professionals and People with ALS (EUpALS) ivzw

Registered office: Vaartkom 17, B-3000 Leuven, Belgium

Enterprise number BE 0684.923.631 – Commercial Tribunal of Leuven

Tel: +32 (0)16-23 95 82 – info@ALS.eu – www.ALS.eu